Journal
PEDIATRIC TRANSPLANTATION
Volume 18, Issue 6, Pages 602-608Publisher
WILEY-BLACKWELL
DOI: 10.1111/petr.12309
Keywords
severe combined immunodeficiency; plerixafor; haploidentical; engraftment
Categories
Funding
- NIH/NCRR UCSF-CTSI [UL1 RR024131]
- UCSF Jeffrey Modell Foundation Diagnostic Center for Primary Immunodeficiencies
Ask authors/readers for more resources
For infants with SCID, the ideal conditioning regimen before allogeneic HCT would omit cytotoxic chemotherapy to minimize short- and long-term complications. We performed a prospective pilot trial with G-CSF plus plerixafor given to the host to mobilize HSC from their niches. We enrolled six patients who received CD34-selected haploidentical cells and one who received T-replete matched unrelated BM. All patients receiving G-CSF and plerixafor had generally poor CD34(+) cell and Lin -CD34(+) CD38(-)CD90(+) CD45RA(-) HSC mobilization, and developed donor T cells, but no donor myeloid or B-cell engraftment. Although well tolerated, G-CSF plus plerixafor alone failed to overcome physical barriers to donor engraftment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available